Cancer incidence is rising around the world while its diagnosis becomes more complex and nuanced , causing heavy workloads for pathologists and laboratories . The increasing demand is compounded by a global shortage of pathologists who still rely heavily on manual work and solely on visual analysis of biopsies . Ibex ' s Galen platform helps overcome these challenges with

AI-powered workflows and decision support tools that pathologists use in their everyday practice .

Ibex ' s Galen platform is the most widely deployed AI technology in pathology and has been deployed in laboratories and pathology departments around the world .

Ibex achieved several significant milestones recently , including live deployment of Galen at University of Pittsburgh Medical Center ( UPMC ), the completion of national roll out throughout Wales and collaboration with AstraZeneca and Daiichi Sankyo for the development of an AI-powered biomarker scoring product for breast cancer . Galen provides health systems and diagnostic laboratories with an integrated solution for cancer diagnosis and biomarker scoring , capable of detecting more the 100 different cancer and non-cancer pathologies while offering enhanced interoperability with scanning systems , image management solutions and lab information systems . Ibex was recently showcased in a KLAS Research report which provided consistently favourable feedback from global customers .

" Ibex is leading the market in live customer deployments as we remain steadfast in our mission of providing every patient with a timely , accurate and personalized cancer diagnosis ," said Joseph Mossel , Co-founder and CEO of Ibex . " This latest financing round will enable us to take major steps toward reaching our goal . We will be using the funds to expand our footprint in the United States to meet the increasing demand for AI-powered diagnostic solutions , and to accelerate the growth of our product portfolio to create more tools for pathologists and labs as they digitally transform their practices . This financing round highlights our strong commercial momentum and our tenacity in pursuing the opportunities that lie ahead ." �

52 www . intelligenthealth . tech